PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 22, 2026Clinical Cancer Research0 citations

Breast Cancer Index Re-stratifies 21-Gene Assay Risk Groups for Recurrence and Therapy Benefit

Abstract PS3-07-24: Breast Cancer Index re-stratifies 21-gene assay risk groups for risk of recurrence and extended endocrine therapy benefit: Final Analysis of the BCI Registry Study

View Full Paper

Authors

VCValerie ChuyNSN. SiuliukinaBOB. O'Neal

Discussion

Loading...

Member takes

Overview

Analysis compares Breast Cancer Index and 21-gene assay for predicting recurrence risk in hormone receptor-positive patients, indicating its clinical relevance.

Key Points

  • To evaluate the concordance between the Breast Cancer Index (BCI) and the 21-gene assay in predicting risk of distant recurrence in hormone receptor-positive early-stage breast cancer.
  • Conducted a prospective, multi-institutional BCI Registry study with over 3400 patients.
  • Evaluated BCI score, H/I ratio, and recurrence score (RS) for risk stratification.
  • Utilized Kendall’s correlation coefficient and Cohen’s kappa for statistical analysis.
  • Reported results for 1238 patients with varied age and risk factors.
  • Observed low correlation between BCI score, H/I ratio, and RS with coefficients around 0.2.
  • Identified significant differences in predicted benefits from extended endocrine therapy based on H/I ratio among older women.
Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Chuy et al. (2026) studied this question.

synapsesocial.com/papers/699a9dae482488d673cd3c49https://doi.org/10.1158/1557-3265.sabcs25-ps3-07-24
Ask AI
Helpful
Bookmark
Share
View Full Paper